The stock of Cullinan Therapeutics Inc (CGEM) has gone up by 19.78% for the week, with a 2.87% rise in the past month and a -25.43% drop in the past quarter. The volatility ratio for the week is 7.44%, and the volatility levels for the past 30 days are 6.01% for CGEM. The simple moving average for the last 20 days is 4.73% for CGEM’s stock, with a simple moving average of -27.48% for the last 200 days.
Is It Worth Investing in Cullinan Therapeutics Inc (NASDAQ: CGEM) Right Now?
CGEM has 36-month beta value of -0.17. Analysts have mixed views on the stock, with 8 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CGEM is 37.06M, and currently, short sellers hold a 26.05% ratio of that float. The average trading volume of CGEM on December 27, 2024 was 491.38K shares.
CGEM) stock’s latest price update
The stock price of Cullinan Therapeutics Inc (NASDAQ: CGEM) has jumped by 5.13 compared to previous close of 12.27. Despite this, the company has seen a gain of 19.78% in its stock price over the last five trading days. globenewswire.com reported 2024-11-14 that Cullinan will present new in vitro preclinical data that provide further strong rationale for broad clinical development of CLN-978 in autoimmune diseases
Analysts’ Opinion of CGEM
Many brokerage firms have already submitted their reports for CGEM stocks, with UBS repeating the rating for CGEM by listing it as a “Buy.” The predicted price for CGEM in the upcoming period, according to UBS is $30 based on the research report published on October 24, 2024 of the current year 2024.
Stifel, on the other hand, stated in their research note that they expect to see CGEM reach a price target of $40. The rating they have provided for CGEM stocks is “Buy” according to the report published on May 01st, 2024.
CGEM Trading at -8.60% from the 50-Day Moving Average
After a stumble in the market that brought CGEM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -57.27% of loss for the given period.
Volatility was left at 6.01%, however, over the last 30 days, the volatility rate increased by 7.44%, as shares surge +1.02% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -20.57% lower at present.
During the last 5 trading sessions, CGEM rose by +19.78%, which changed the moving average for the period of 200-days by -23.85% in comparison to the 20-day moving average, which settled at $12.32. In addition, Cullinan Therapeutics Inc saw 26.59% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CGEM starting from Michaelson Jennifer, who sale 4,693 shares at the price of $11.41 back on Dec 18 ’24. After this action, Michaelson Jennifer now owns 99,760 shares of Cullinan Therapeutics Inc, valued at $53,547 using the latest closing price.
Jones Jeffrey Alan, the Chief Medical Officer of Cullinan Therapeutics Inc, sale 4,632 shares at $11.41 during a trade that took place back on Dec 18 ’24, which means that Jones Jeffrey Alan is holding 114,059 shares at $52,851 based on the most recent closing price.
Stock Fundamentals for CGEM
The total capital return value is set at -0.3. Equity return is now at value -26.18, with -25.01 for asset returns.
Currently, EBITDA for the company is -190.34 million with net debt to EBITDA at 0.53. The liquidity ratio also appears to be rather interesting for investors as it stands at 24.46.
Conclusion
To put it simply, Cullinan Therapeutics Inc (CGEM) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
